Table 2.
Results of univariate analysis for locoregional recurrence and disease-free survival.
| Variable | LRR | DFS | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age (years) | 0.965 | 0.173 | ||
| <50 | 1 (ref) | 1 (ref) | ||
| ≥50 | 0.988 (0.589–1.659) | 1.243 (0.909–1.698) | ||
| Tumour size, cm | 0.01 | ≤0.001 | ||
| <4 | 1 (ref) | 1 (ref) | ||
| ≥r | 2.355 (1.404–3.952) | 1.758 (1.286–2.403) | ||
| Tumour grade | 0.015 | 0.488 | ||
| G1-G2 | 1 (ref) | 1 (ref) | ||
| G3 | 2.377 (1.182–4.778) | 1.203 (0.713–2.031） | ||
| Histological type | 0.806 | 0.035 | ||
| Ductal | 1 (ref) | 1 (ref) | ||
| Tubular | 1.097 (0.0396–3.039) | 1.132 (0.613–2.089） | ||
| Others | 0.692 (0.216–2.217) | 0.302 (0.112–0.814） | ||
| LVI | 0.093 | ≤0.001 | ||
| Yes | 1 (ref) | 1 (ref) | ||
| No | 0.557 (0.282–1.103) | 0.486 (0.327–0.723） | ||
| Clinical N stage | 0.461 | 0.007 | ||
| N0 | 1 (ref) | 1 (ref) | ||
| N1 | 1.401 (0.733–2.676) | 1.979 (1.292–3.031） | ||
| N2 | 0.97 (0.382–2.465) | 1.624 (0.937–2.812） | ||
| Clinical TNM stage | 0.044 | 0.002 | ||
| Stage II | 1 (ref) | 1 (ref) | ||
| Stage III | 1.718 (1.015–2.907) | 1.651 (1.205–2.260） | ||
| ER status | 0.405 | 0.901 | ||
| ER+ | 1 (ref) | 1 (ref) | ||
| ER− | 1.249 (0.743–2.101) | 1.020 (0.746–1.395） | ||
| PR status | 0.002 | 0.033 | ||
| PR+ | 1 (ref) | 1 (ref) | ||
| PR− | 2.428 (1.379–4.276) | 1.400 (1.027–1.909） | ||
| HER-2 status | 0.483 | 0.094 | ||
| HER-2 positive | 1 (ref) | 1 (ref) | ||
| HER-2 negative | 0.797 (0.424–1.500) | 0.726 (0.499–1.056） | ||
| TNBC | 0.017 | 0.006 | ||
| TNBC | 1 (ref) | 1 (ref) | ||
| No TNBC | 0.485 (0.268–0.878) | 0.592 (0.405–0.863) | ||
| Clinical tumour response | 0.012 | 0.273 | ||
| CR + PR | 1 (ref) | 1 (ref) | ||
| SD + PD | 2.126 (1.180–3.831) | 1.255 (0.836–1.886） | ||
| Pathological response | 0.162 | 0.010 | ||
| pCR | 1 (ref) | 1 (ref) | ||
| No pCR | 4.099 (0.567–29.615) | 6.262 (1.553–25.256） | ||
| Pathological N stage | ≤0.001 | ≤0.001 | ||
| N0 | 1 (ref) | 1 (ref) | ||
| N1 | 1.712 (0.79–3.711) | 1.753 (1.085–2.832） | ||
| N2 | 2.547 (1.166–5.565) | 3.554 (2.231–5.662） | ||
| N3 | 5.644 (2.472–12.882) | 7.249 (4.371–12.022） | ||
| PMRT | 0.013 | 0.993 | ||
| RT | 1 (ref) | 1 (ref) | ||
| No RT | 1.935 (1.147–3.266） | 0.999 (0.708–1.407） | ||
| Anti-HER-2 therapy | 0.629 | 0.983 | ||
| Yes | 1 (ref) | 1 (ref) | ||
| 0.751 (0.235–2.401） | 1.007 (0.546–1.856） | |||
| Adjuvant chemotherapy | 0.184 | 0.524 | ||
| Yes | 1 (ref) | 1 (ref) | ||
| No | 1.238 (0.903–1.695） | 1.083 (0.847–1.384） | ||
| Endocrinotherapy | 0.218 | 0.121 | ||
| Yes | 1 (ref) | 1 (ref) | ||
| No | 1.119 (0.935–1.339） | 1.093 (0.977–1.223） | ||
LRR, locoregional recurrence rates; DFS, disease-free survival; HR, hazard ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor; TNBC, triple-negative breast cancer; pCR, pathological complete response; CR, complete response; PR, partial response; SD, stable disease; PD, progress disease.